Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

The U.S. Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients ...

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the world’s first low-carbon version of a triple-combination inhaler for chronic obstructive pulmonary disease (COPD).

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of ...

Poor treatment of asthma and COPD puts a huge burden on the NHS. For example, £1 billion is spent on asthma treatment in the UK each year and represents 60,000 to 65,000 hospital admissions. In ...

making smoking cessation a critical part of treatment along with medications, oxygen therapy, and lifestyle changes Chronic obstructive pulmonary disease, commonly referred to as COPD, is a group ...

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

AstraZeneca's Breztri Aerosphere in India is made using a new type of gas (called a next-generation propellant) that does not contribute much to climate change.